DKSH and Bayer expand its collaboration to Singapore

DKSH, the leading Market Expansion Services provider with a focus on Asia, has signed an agreement with Bayer, a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials, to provide tailor-made services for their market expansion in Singapore.

Singapore – DKSH Business Unit Healthcare, a leading partner for healthcare companies seeking to grow their business in Asia, has signed an agreement with Bayer Thai to provide services for Bayer's products in Singapore.

DKSH Healthcare already provides Market Expansion Services for Bayer's Consumer Care and Pharmaceuticals Divisions in Thailand, China and Cambodia.

"We are delighted to further expand our excellent collaboration with Bayer to Singapore. Our expertise and quality in healthcare distribution optimally complements Bayer's marketing and sales expertise for high-quality products. Through our combined strengths, both companies will be able to expand and grow in the market," commented Lina Chua, General Manager, Business Unit Healthcare, DKSH Singapore.

The agreement between DKSH and Bayer underlines DKSH's ability to replicate success stories and expand partnerships across markets in Asia. The agreement will further strengthen DKSH's market position in Singapore while contributing incrementally to the Group's overall profitability over time.

About Bayer

Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. As an innovation company, it sets trends in research-intensive areas. Bayer's products and services are designed to benefit people and improve the quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and acts as a socially and ethically responsible corporate citizen. In fiscal 2012, the Group employed 110,500 people and had sales of €39.8 billion. Capital expenditures amounted to €2.0 billion, R&D expenses to €3.0 billion.

About DKSH

DKSH is the leading Market Expansion Services provider with a focus on Asia. As the term "Market Expansion Services" suggests, DKSH helps other companies and brands to grow their business in new or existing markets.


Publicly listed on the SIX Swiss Exchange since March 2012, DKSH is a global company headquartered in Zurich. With 680 business locations in 35 countries – 660 of them in Asia – and 26,300 specialized staff, DKSH generated net sales of CHF 8.8 billion in 2012.

DKSH Business Unit Healthcare is the leading Market Expansion Services provider for healthcare companies seeking to grow their business in Asia. Custom-made offerings comprise registration and market entry studies as well as importation, customs clearance, marketing and sales to physical distribution, invoicing and cash collection. Products available through DKSH Healthcare include ethical pharmaceuticals, consumer health, over-the-counter (OTC), as well as medical devices. With 150 business locations in 13 countries and around 9,000 specialized staff, Business Unit Healthcare serves over 160,000 customers and generated net sales of around CHF 3.7 billion in 2012.

 

Suggested Articles

Genesis Drug Discovery & Development has bought up New England Discovery Partners as it looks to boost its synthetic and medicinal chemistry.

Sanofi plans to incorporate its real-world data platform with Aetion’s analytics system to better develop studies for regulatory decision-making.

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.